Teens with HIV are having more risky sex with more partners than their counterparts did in the years before powerful new medications for HIV were introduced in 1996, according to a new report in the American Journal of Health Behavior.

A group of HIV-positive youth studied between 1999 and 2000 reported having more sexual partners, more unprotected sex and more drug use than HIV-positive youth studied between 1994 and 1996, say Marguerita Lightfoot, Ph.D. and colleagues at the UCLA AIDS Institute at the David Geffen School of Medicine.

High throughput microarray analyses result in many differentially expressed genes that are potentially responsible for the biological process of interest. In order to identify biological similarities between genes, publications from MEDLINE were identified in which pairs of gene names and combinations of gene name with specific keywords were co-mentioned.

Biologists at the University of Liverpool have discovered how the plagues of the Middle Ages have made around 10% of Europeans resistant to HIV. Scientists have known for some time that these individuals carry a genetic mutation (known as CCR5-delta32) that prevents the virus from entering the cells of the immune system but have been unable to account for the high levels of the gene in Scandinavia and relatively low levels in areas bordering the Mediterranean.

AmCyte Inc. (www.amcyte.com), a leader in encapsulated islet replacement and pancreatic adult stem cells, announced today the transplantation of the first Type 1 diabetic patient in North America to receive islets without long-term immune suppression.

The transplant took place on February 22nd at Toronto General Hospital. The patient experienced no complications during the minor 20-minute surgical infusion. The patient was released from the hospital three days after the procedure and is resting at home.....

Research at Northwestern University Feinberg School of Medicine played a significant role in Food and Drug Administration approval of Abraxane (paclitaxel protein-bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer. "The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel," said principal clinical study investigator William J. Gradishar, M.D., associate professor of medicine, division of hematology/oncology at Feinberg and co-director, Lynn Sage Breast Cancer Program at Northwestern Memorial Hospital.